FI118512B - Flutikasonpropionatformulationer - Google Patents
Flutikasonpropionatformulationer Download PDFInfo
- Publication number
- FI118512B FI118512B FI964634A FI964634A FI118512B FI 118512 B FI118512 B FI 118512B FI 964634 A FI964634 A FI 964634A FI 964634 A FI964634 A FI 964634A FI 118512 B FI118512 B FI 118512B
- Authority
- FI
- Finland
- Prior art keywords
- formulation
- sorbitan monolaurate
- formulation according
- polyoxyethylene
- fluticasone propionate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (16)
1. Suspensionsformulation, som lärapar sig för ne-bulisering för administration av en verksam formulations- 5 mängd till lungorna, kännetecknad av att den omfattar (a) fluticasonpropionat som är väsentligen helt och hället till sin partikelstorlek under 12 μπι,- (b) ett eller flera ytaktiva airmen; 10 (c) ett eller flera buffertmedel; (d) vatten.
2. Formulation enligt patentkrav 1, kännetecknad av att fluticasonpropionatets partikelstorlek är 1 - 6 μη.
3. Formulation enligt patentkrav 1 eller 2, kän netecknad av att 0,5 - 10 vikt-% fluticasonpropionat är närvarande beräknat pä den totala mängden fasta ingre-dienser i formulationen.
4. Formulation enligt nägot av patentkraven 1-3, 20 kännetecknad av att formulationen innehäller tvä ytaktiva ämnen.
,·. 5. Formulation enligt nägot av patentkraven 1-4, kännetecknad av att 0,25 - 0,75 vikt-% ytaktivt ämne • · * ! är närvarande beräknat pä den totala mängden fasta ingre- • * · *···* 25 dienser i formulationen.
«·· ···· 6. Formulation enligt nägot av de föregäende pa- tentkraven, kännetecknad av att som ytaktiva ämnen V : kommer sorbitantrioleat, sorbitanmonooleat, sorbitanmono- laurat, polyoxieten(20)sorbitanmonolaurat, polyoxieten- 30 (20) sorbi tanmonooleat, naturligt lecitin, oleylpolyoxie- ten(2)eter, stearylpolyoxieten(2)eter, laurylpolyoxieten- ·* (4)eter, blockpolymerer av oxieten och oxipropen, synte- • t · *·|#* tiskt lecitin, dietenglykoldioleat, tetrahydrofuryloleat, • · etyloleat, glycerylmonooleat, polyetenglykol 400 och gly- * 35 cerylmonolaurat pä fräga. • · • · 118512
7. Formulation enligt patentkrav 6, känneteck-n a d av att de ytaktiva ämnena är sorbitanmonolaurat och polyoxieten(20)sorbitanmonolaurat.
8. Formulation enligt patentkrav 7, känneteck- 5 nad av att sorbitanmonolaurat och polyoxieten(20)sorbi- tanmonolaurat är närvarande i förhällandet 1:7,5 - 1:8,25.
9. Formulation enligt nägot av de föregäende pa-tentkraven, kännetecknad av att den är buff rad tili ett pH-värde pä cirka 5-7.
10. Formulation enligt nägot av de föregäende pa- tentkraven, kännetecknad av att den är isoton.
11. Formulation enligt nägot av de föregäende pa-tentkraven, kännetecknad av att den omfattar (a) 0,25 - 1,1 mg/ml fluticasonpropionat (mikroni- 15 serat); (b) 0,06 - 0,09 mg/ml polyoxieten(20)sorbitanmonolaurat ; (c) 0,0075 - 0,0125 mg/ml sorbitanmonolaurat,- (d) 9,25 - 9,5 mg/ml mononatriumfosfatdihydrat; 20 (e) 1,6 - 1,85 mg/ml vattenfritt tväbasiskt natri- umfosfat; (f) 4,7 - 4,9 mg/ml natriumklorid; och « II1I (g) vatten. • · * I
12. Formulation enligt patentkrav 11, kanne- **"1 25 tecknad av att den omfattar ca ··· ··1! (a) 0,26 mg/ml fluticasonproprionat (mikronise- *.!.1 rat) ; • tt V : (b) 0,07 mg/ml polyoxieten(20) sorbitanmonolaurat,- (c) 0,009 mg/ml sorbitanmonolaurat; 30 (d) 9,4 mg/ml mononatriumfosfatdihydrat; :'**· (e) 1,75 mg/ml vattenfritt tväbasiskt natriumfos- • · · f at; • · 1 *;]t1 (f) 4,8 mg/ml natriumklorid; och • · **··1 (g) vatten. • · • · · • · · • I · 118512
13. Formulation enligt patentkrav 11, kanne -tecknad av att den omfattar ca (a) 1,05 mg/ml fluticasonpropionat (mikroniserat); (b) 0,08 mg/ml polyoxieten(20)sorbitanmonolaurat; 5 (c) 0,01 mg/ml sorbitanmonolaurat; (d) 9,4 mg/ml mononatriumfosfatdihydrat; (e) 1,75 mg/ml vattenfritt tväbasiskt natriumfos- fat; (f) 4,8 mg/ml natriumklorid; och 10 (g) vatten.
14. Förfarande för framställning av en formulation enligt nägot av de föregäende patentkraven, känneteck-nat av att fluticasonpropionat bringas i kontakt med en lösning av ytaktivt ämne och den som resultat erhällna 15 lösningen av läkemedel och ytaktivt ämne blandas med for-mulationens övriga ingredienser.
15. Behällare, kännetecknad av att den inne-häller en formulation enligt nägot av patentkraven 1 - 13.
16. Användning av en formulation enligt nägot av 20 patentkraven 1-13 i en nebulisator för bildande av ett flertal droppar bestäende av nämnda formulation, vilka droppar är lämpliga för inhalation. ···· ·· · « · · • 1 • · » t · • · · ··· « • · · Ml» • · 1 • · · *·· • · · I f · • · · ·1 • · • ·· ΦΦ1 • · • Φ • Φ · • ··· • · · • · · ··· • · • t • · · • · · « « 1 • 1· • ·
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9410222A GB9410222D0 (en) | 1994-05-21 | 1994-05-21 | Medicaments |
| GB9410222 | 1994-05-21 | ||
| PCT/EP1995/001913 WO1995031964A1 (en) | 1994-05-21 | 1995-05-19 | Fluticasone propionate formulations |
| EP9501913 | 1995-05-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI964634A FI964634A (sv) | 1996-11-20 |
| FI964634A0 FI964634A0 (sv) | 1996-11-20 |
| FI118512B true FI118512B (sv) | 2007-12-14 |
Family
ID=10755515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI964634A FI118512B (sv) | 1994-05-21 | 1996-11-20 | Flutikasonpropionatformulationer |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5993781A (sv) |
| EP (1) | EP0760649B1 (sv) |
| JP (1) | JPH10500420A (sv) |
| KR (2) | KR100361413B1 (sv) |
| CN (1) | CN1098680C (sv) |
| AT (1) | ATE207734T1 (sv) |
| AU (1) | AU710821B2 (sv) |
| BR (1) | BR9507746A (sv) |
| CA (1) | CA2190763A1 (sv) |
| CY (1) | CY2294B1 (sv) |
| CZ (1) | CZ285966B6 (sv) |
| DE (1) | DE69523587T2 (sv) |
| DK (1) | DK0760649T3 (sv) |
| ES (1) | ES2164767T3 (sv) |
| FI (1) | FI118512B (sv) |
| GB (1) | GB9410222D0 (sv) |
| HK (1) | HK1004192A1 (sv) |
| HU (1) | HU223316B1 (sv) |
| IL (1) | IL113794A (sv) |
| MX (1) | MX9605650A (sv) |
| NO (1) | NO313785B1 (sv) |
| NZ (1) | NZ287425A (sv) |
| PL (1) | PL180318B1 (sv) |
| PT (1) | PT760649E (sv) |
| RU (1) | RU2161485C2 (sv) |
| SI (1) | SI0760649T1 (sv) |
| TW (1) | TW438604B (sv) |
| WO (1) | WO1995031964A1 (sv) |
| ZA (1) | ZA954101B (sv) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE274341T1 (de) * | 1995-02-24 | 2004-09-15 | Elan Pharma Int Ltd | Nanopartikel-dispersionen enthaltende aerosole |
| GB9610341D0 (en) * | 1996-05-17 | 1996-07-24 | Andaris Ltd | Formulation for inhalation |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US8820316B2 (en) * | 2000-02-11 | 2014-09-02 | Respironics Respiratory Drug Delivery (Uk) Ltd | Drug delivery apparatus |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| EP1458360B1 (en) | 2001-12-19 | 2011-05-11 | Novartis AG | Pulmonary delivery of aminoglycosides |
| JP4598399B2 (ja) | 2002-02-04 | 2010-12-15 | エラン ファーマ インターナショナル，リミティド | 表面安定剤としてリゾチームを有するナノ粒子組成物 |
| DK1476201T3 (da) | 2002-02-19 | 2009-03-30 | Resolution Chemicals Ltd | Solvent-baseret sterilisering af steroider |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| EP1454636A1 (en) * | 2003-03-04 | 2004-09-08 | Dompé S.P.A. | Sterilization of glucocorticoid drug particles for pulmonary delivery |
| US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| WO2004105809A1 (en) * | 2003-05-22 | 2004-12-09 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| DE602005026225D1 (de) | 2004-03-12 | 2011-03-24 | Cipla Ltd | Sterilisationsprozess für Steroide |
| GB0410995D0 (en) | 2004-05-17 | 2004-06-23 | Norton Healthcare Ltd | Heat sterilization of glucocorticosteroids |
| GB0425266D0 (en) | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
| GB0427568D0 (en) * | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
| US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
| CN102166219B (zh) * | 2010-05-25 | 2013-04-17 | 杭州天龙药业有限公司 | 一种鼻腔给药制剂及其应用 |
| EP2847207B1 (en) | 2012-05-08 | 2019-03-27 | Nicox Ophthalmics, Inc. | Fluticasone propionate nanocrystals |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| CN103505412A (zh) * | 2012-06-26 | 2014-01-15 | 上海臣邦医药科技有限公司 | 一种吸入用丙酸氟替卡松混悬液的制备方法 |
| US10111957B2 (en) | 2012-07-05 | 2018-10-30 | Arven Ilac Snayi ve Ticaret A.S. | Inhalation compositions comprising glucose anhydrous |
| WO2014007781A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| US20150165037A1 (en) | 2012-07-05 | 2015-06-18 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising corticosteroid and sorbitol |
| DE102012111077A1 (de) * | 2012-11-16 | 2014-05-22 | Justus-Liebig-Universität Giessen | Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| RS58897B1 (sr) | 2014-09-15 | 2019-08-30 | Verona Pharma Plc | Tečna inhalaciona formulacija koja sadrži rpl554 |
| WO2019241580A1 (en) | 2018-06-14 | 2019-12-19 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| ATE128350T1 (de) * | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung. |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| CA2356145A1 (en) * | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
| US5301664A (en) * | 1992-03-06 | 1994-04-12 | Sievers Robert E | Methods and apparatus for drug delivery using supercritical solutions |
| GB9419536D0 (en) * | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
-
1994
- 1994-05-21 GB GB9410222A patent/GB9410222D0/en active Pending
-
1995
- 1995-05-19 PL PL95317225A patent/PL180318B1/pl unknown
- 1995-05-19 HU HU9603227A patent/HU223316B1/hu active IP Right Grant
- 1995-05-19 NZ NZ287425A patent/NZ287425A/en not_active IP Right Cessation
- 1995-05-19 CA CA002190763A patent/CA2190763A1/en not_active Abandoned
- 1995-05-19 JP JP7530051A patent/JPH10500420A/ja active Pending
- 1995-05-19 PT PT95920841T patent/PT760649E/pt unknown
- 1995-05-19 KR KR1019960706578A patent/KR100361413B1/ko not_active IP Right Cessation
- 1995-05-19 SI SI9530550T patent/SI0760649T1/xx unknown
- 1995-05-19 BR BR9507746A patent/BR9507746A/pt not_active IP Right Cessation
- 1995-05-19 ES ES95920841T patent/ES2164767T3/es not_active Expired - Lifetime
- 1995-05-19 WO PCT/EP1995/001913 patent/WO1995031964A1/en active IP Right Grant
- 1995-05-19 CN CN95193201A patent/CN1098680C/zh not_active Expired - Lifetime
- 1995-05-19 EP EP95920841A patent/EP0760649B1/en not_active Expired - Lifetime
- 1995-05-19 AU AU26145/95A patent/AU710821B2/en not_active Expired
- 1995-05-19 CZ CZ963423A patent/CZ285966B6/cs not_active IP Right Cessation
- 1995-05-19 ZA ZA954101A patent/ZA954101B/xx unknown
- 1995-05-19 DE DE69523587T patent/DE69523587T2/de not_active Expired - Lifetime
- 1995-05-19 MX MX9605650A patent/MX9605650A/es unknown
- 1995-05-19 US US08/737,592 patent/US5993781A/en not_active Expired - Lifetime
- 1995-05-19 KR KR1019960706549A patent/KR970703132A/ko not_active Application Discontinuation
- 1995-05-19 IL IL11379495A patent/IL113794A/xx not_active IP Right Cessation
- 1995-05-19 DK DK95920841T patent/DK0760649T3/da active
- 1995-05-19 RU RU96124389/14A patent/RU2161485C2/ru active
- 1995-05-19 AT AT95920841T patent/ATE207734T1/de active
- 1995-06-17 TW TW084106242A patent/TW438604B/zh not_active IP Right Cessation
-
1996
- 1996-11-20 FI FI964634A patent/FI118512B/sv not_active IP Right Cessation
- 1996-11-20 NO NO19964938A patent/NO313785B1/no not_active IP Right Cessation
-
1998
- 1998-04-27 HK HK98103532A patent/HK1004192A1/xx not_active IP Right Cessation
-
2002
- 2002-09-02 CY CY0200053A patent/CY2294B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI118512B (sv) | Flutikasonpropionatformulationer | |
| AU749751B2 (en) | Pulmonary and nasal delivery of raloxifene | |
| US9724382B2 (en) | Pharmaceutical compositions comprising cyclosporin | |
| US20090041676A1 (en) | Targeted Delivery of Lidocaine and Other Local Anesthetics and A Method For Treatment of Cough, Asthma and Tussive Attacks | |
| WO2006036180A1 (en) | Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks | |
| US6187765B1 (en) | Mometasone furoate suspensions for nebulization | |
| EP1033991B1 (en) | Mometasone furoate suspensions for nebulization | |
| US20050042171A1 (en) | Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma | |
| MX2013004030A (es) | Composicion farmaceutica a base de denufosol para tratar fibrosis quistica. | |
| CN113350323A (zh) | 一种用于抑制冠状病毒的吸入剂及其制备方法和应用 | |
| JP6908523B2 (ja) | ネブライザー用組成物 | |
| US20040039020A1 (en) | Novel pharmaceutical formulation suitable for nebulisation | |
| EA042761B1 (ru) | Способ лечения заболеваний легких и набор | |
| EA044593B1 (ru) | Ингаляционные композиции, содержащие макроциклические иммуносупрессанты | |
| MXPA00009704A (en) | Pulmonary and nasal delivery of raloxifene | |
| CZ20003544A3 (cs) | Pulmonární a nasální podávání raloxifenu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 118512 Country of ref document: FI |
|
| MA | Patent expired |